ZA843584B - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
ZA843584B
ZA843584B ZA843584A ZA843584A ZA843584B ZA 843584 B ZA843584 B ZA 843584B ZA 843584 A ZA843584 A ZA 843584A ZA 843584 A ZA843584 A ZA 843584A ZA 843584 B ZA843584 B ZA 843584B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA843584A
Other languages
English (en)
Inventor
John Malcolm Padfield
Ian Keith Winterborn
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10542680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA843584(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA843584B publication Critical patent/ZA843584B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
ZA843584A 1983-05-13 1984-05-11 Pharmaceutical compositions ZA843584B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838313217A GB8313217D0 (en) 1983-05-13 1983-05-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA843584B true ZA843584B (en) 1985-12-24

Family

ID=10542680

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA843584A ZA843584B (en) 1983-05-13 1984-05-11 Pharmaceutical compositions

Country Status (20)

Country Link
US (1) US4585790A (da)
JP (1) JPH0639378B2 (da)
AU (1) AU568647B2 (da)
BE (1) BE899635A (da)
CA (1) CA1216240A (da)
CH (1) CH662272A5 (da)
CZ (1) CZ281598B6 (da)
DE (1) DE3417606C2 (da)
DK (1) DK165663B (da)
FR (1) FR2547727B1 (da)
GB (2) GB8313217D0 (da)
IE (1) IE57397B1 (da)
IL (1) IL71813A (da)
IT (1) IT1179367B (da)
NL (1) NL194429C (da)
NZ (1) NZ208127A (da)
PH (1) PH20574A (da)
SE (1) SE459898B (da)
SK (1) SK279526B6 (da)
ZA (1) ZA843584B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations
GB9715423D0 (en) * 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
BR0108080A (pt) * 2000-02-04 2006-02-07 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
JP4374250B2 (ja) * 2001-12-27 2009-12-02 テルモ株式会社 ファモチジン注射液
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
ATE458489T1 (de) * 2004-08-30 2010-03-15 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
ATE506955T1 (de) * 2004-10-15 2011-05-15 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
WO2006050165A2 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装
WO2007022105A2 (en) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
WO2008039792A1 (en) * 2006-09-25 2008-04-03 Scidose Llc Stable pharmaceutical compositions of preserved formulation of ranitidine, process for making the same, and methods of their use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP2925305B1 (en) 2013-12-04 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626054A (en) * 1967-10-25 1971-12-07 Bard Hamilton Co Inc Lupus erythematosus skin test
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4203909A (en) * 1978-09-26 1980-05-20 Bristol-Myers Company Furan compounds
DE3108753A1 (de) * 1981-03-07 1982-09-16 Degussa Ag, 6000 Frankfurt Neue substituierte alkyl-phenylsulfonylguanidine miteinem heterocyclischen rest

Also Published As

Publication number Publication date
DE3417606A1 (de) 1984-11-15
IE841179L (en) 1984-11-13
AU568647B2 (en) 1988-01-07
DK165663B (da) 1993-01-04
SK279526B6 (sk) 1998-12-02
JPH0639378B2 (ja) 1994-05-25
BE899635A (fr) 1984-11-12
IL71813A0 (en) 1984-09-30
PH20574A (en) 1987-02-18
IT1179367B (it) 1987-09-16
SE459898B (sv) 1989-08-21
SE8402560D0 (sv) 1984-05-11
GB2142820B (en) 1987-01-14
IT8448182A0 (it) 1984-05-11
DE3417606C2 (de) 1996-03-14
CS403691A3 (en) 1992-08-12
CA1216240A (en) 1987-01-06
FR2547727A1 (fr) 1984-12-28
DK237884D0 (da) 1984-05-11
IL71813A (en) 1988-03-31
IE57397B1 (en) 1992-08-26
FR2547727B1 (fr) 1988-02-26
NL194429B (nl) 2001-12-03
GB8313217D0 (en) 1983-06-22
JPS59219225A (ja) 1984-12-10
DK237884A (da) 1984-11-14
NL194429C (nl) 2002-04-04
GB8412108D0 (en) 1984-06-20
CZ281598B6 (cs) 1996-11-13
NZ208127A (en) 1987-05-29
NL8401524A (nl) 1984-12-03
CH662272A5 (fr) 1987-09-30
SE8402560L (sv) 1984-11-14
GB2142820A (en) 1985-01-30
US4585790A (en) 1986-04-29
AU2792984A (en) 1984-11-15

Similar Documents

Publication Publication Date Title
GB2136807B (en) Pharmaceutical compositions
GB8423339D0 (en) Pharmaceutical compositions
GB8403668D0 (en) Pharmaceutical compositions
DE3467703D1 (en) Pharmaceutical compositions
GB8313217D0 (en) Pharmaceutical compositions
GB8325494D0 (en) Pharmaceutical compositions
GB8415975D0 (en) Pharmaceutical compositions
GB8308126D0 (en) Pharmaceutical compositions
GB8325496D0 (en) Pharmaceutical compositions
HK97492A (en) Pharmaceutical compositions
GB2136806B (en) Pharmaceutical compositions
GB8414458D0 (en) Pharmaceutical compositions
CY1503A (en) Pharmaceutical compositions
GB8412569D0 (en) Pharmaceutical compositions
GR80223B (en) Pharmaceutical compositions
GB8406132D0 (en) Pharmaceutical compositions
GR80238B (en) Pharmaceutical compositions
GB8416358D0 (en) Pharmaceutical compositions
GB8305697D0 (en) Pharmaceutical compositions
GB8300767D0 (en) Pharmaceutical compositions
GB8425250D0 (en) Pharmaceutical compositions
GB2150435B (en) Pharmaceutical compositions
IE830600L (en) Pharmaceutical compositions
GB8331776D0 (en) Pharmaceutical compositions
GB8331425D0 (en) Pharmaceutical compositions